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Introduction
hlorambucil is an alkylating agent, it forms a covalent bond with proteins causing structural and functional damage to DNA especially of tumor cells so, it is used in therapy of oncologic diseases (Pangalis et al., 2002) Chlorambucil (4-(4-(Bis(2-chlorethyl) amino) phenyl) butanoid acid) is the first choice to be used in treatment of chronic lymphocytic leukemia and low grade non Hodgkin's lymphoma (Li et al., 2010) in a dose of 0.2mg/kg/day(high dose) for 5 consequative days in repeated cycles (ie 5 consequative days per week for 2 weeks with 2days in between, or for 3 weeks with 2 days in between, etc). (Balaram et al., 2012) . It is used also in the same dose and manner as an immunosuppressant in nephrotic syndrome (Guigoniset al.,2008) and before bone marrow trasplantation in myeloma (Anagnostopoulos et al., 2006) and chronic lymphocytic lymphoma with other chemotherapeutics (Tomendedelova et al., 2008) . After oral administration, chlorambucil is rapidly and totally absorbed from gastrointestinal tract, distributed to liver, kidneys and other organs.it is converted in liver by hepatic microsomal enzymes to 3-(4-dehydro-Clorambucil) then to the final metabolite phenyl acetic acid mustard the later is further metabolized to inactive products excreted in urine and feces. (Pangalis et al., 2002) The cytotoxic effects of chlorambucil are due to formation of ethylenimonium radical which causes damage of cellular antioxidant defense system in addition to breaks in DNA and cross linking of its double strands thus interfering with DNA replication and RNA transcription (Mc Evoyed,2006) .
The use of antioxidant in combination of chlorambucil may ameliorate its toxic effects (Singh et al.,2011) Aim of the study is to evaluate the potential protective role of L-ascorbic acid against chlorambucil induced hepatic and renal toxiciies in rats.
Materials and methods
The present study was conducted on 160 adult male albino rats weighing 200±50 gm obtained from Egyptian Organization for Biological Products and Vaccines.They were kept in special animal cages under standardized conditions with free water supply and balanced diet and left for 14 days before the experiment for acclematization. Ethical Consederations of The Study:
The experimental procedure was performed in accordance with the guide of the care and use of laboratory animal 's protocol approved by the Ethical Committee of Ain Shams University .All ethically approved conditions used by animal housing,feeding and handling were considered . The experimental protocol used followed the regulation for adminestration and painless sacrifaction for experimental animals.
Drug, dose and route:
Chlorambucil is a product of Aspen Pharma Trading Limited,Dublin ,Ireland, in the form of 2mg tablets each was grined and diluted in 10 ml saline ,1ml of the solution was administrated to each rat orally by a gastric tube in a dose of 0.2mg/kg/day for 5 consecutive days , and there was 2 days rest after each 5 consecutive days according to (Tomendedelova et al ., 2008) .L-ascorbic acid was obtained from Unipharma in the form of 15 ml solution in a dose of 100mg/kg/day (non toxic dose) according to (Tunde et al., 2014) it was administrated also orally by a gastric tube.
Animal grouping:
The rats were classified into 8 equal groups,20 rats each. Group I: (negative control group) Group II: (L-ascorbic acid group): received L-Ascorbic acid in a dose of 100mg/kg/day for 15 days. Group III:received chlorambucil for 5 days in a dose of 0.2mg/kg/day Group IV: recieved chlorambucil for 10 days in a dose of 0.2mg/kg/day Group V:received Chlorambucil for 15 days in a dose of 0.2mg/kg/day Group VI: received chlorambucil and L-Ascorbic acid for 5 days in doses of 0.2mg/kg/day and 100mg/kg/day respectively. Group VII: received chlorambucil and L-Ascorbic acid for 10 days in doses of 0.2mg/kg/day and 100mg/kg/day respectively. Group VIII: received chlorambucil and L-Ascorbic acid for 15 days in doses of 0.2 mg/kg/day and 100mg/kg/day respectively. Sample Collection:
At the end of each experimental period, each rat group was anaesthesised by ether inhalation to avoid pain, dissection had been performed for all rats,10 ml blood samples were collected from abdominal aorta soon after death, in dry clean centrifuge tubes. Samples were centrifuged and serum was collected for assessing the biochemical parameters. kidneys and liver were dissected out and prepared for GSH assay and histopathological study by light microscopic examination. Hepatic parameters: levels of Serum Aspartate Aminotransferase (ALT), Serum Alanine Aminotransferase (AST) were determined by colorimetric method according to Frankel and Gradwohl (1970) and total bilirubin was measured according to Suber (1994) . The assay kits were purchased from Alkane Company. Kidney parameters: Blood Urea Nitrogen (BUN) and serum createnine were measured by colorimetric method according to Lawrence and Robert (1993) . The assay kits were purchased from Alkane Company.
Histopathological examination:
Glutathoine assay (GSH): Tissue samples were homogenized with ice-cold trichloroacetic acid (1gm tissue plus 10ml 10%TCA)in an UltraTurrax tissue homogenizer. Glutathione measurements were performed using a modification of Ellman procedure (Ghosh et al; . The assay kits were purchased from Alkane company.
The kidneys and the right lobe of the liver were rapidly removed from each animal. They were fixed in 10% formol-saline for one week. This was followed by dehydration, clearing and embedding in paraffin. Serial sections were cut at thickness of 5µm and were stained with hematoxylin and eosin stain (H&E) (Bancroft et al., 1994) Sections were then examined and photographed in the Histology Department, Faculty of Medicine, Ain Shams University using Leica DM2500 microscope (Wetzlar, Germany) connected to a personal computer.
Statistical analysis:
The statistical analysis was performed using standard SPSS(st pacckage for social science)software package, version 20 (Chicago.IL)data were expressd as (mean±SD). Student's t -test ,ANOVA,one way statistical analysis and Chi square (X 2 )were used to analyse the data with p<0.05 and q>4.354 considered statisticaly significant (Taylor,1990) .
Results

Biochemical results
The results depicted in tables 1,2,3,4,5 and 6 showed a comparison of studied biochemical parameters ; hepatic (AST,ALT and total serum bilirubin),renal(BUN and serum creatinine) and hepatic and renal GSH .Among all groups under study, there was insignificant difference in the mean values of all the tested parameters between ( group I ) control group and group II ( received L-ascorbic acid only).While, there was very high significant differense in the mean values of all studied parameters in chlorambucil groups as compared with the control group. Oral administration of L-ascorbic acid concomitantly with chlorambucil (group VI,VII and VIII)markedly increased hepatic and renal parameters and decreased hepatic and renal GSH. When compared with group I, regarding all studied parameters, group VI showed significant difference,group VII showed higher significant difference -except serum createnine where it showed very high significant difference-and group VIII showed very high significant difference.
When group III (received chlorambucil for 5 days) was compared with group VI(received L-ascorbic acid concomitantly with chlorambucil for 5 days), regarding hepatic biochemical parameters, high significant difference was observed.While regarding renal biochemical parameters and tissue GSH, a very high significant difference was found.
Comparing group IV(received chlorambucil for 10 days) and group VII (received L-ascorbic acid concomitantly with chlorambucil for 10 days), regarding all studied parameters, a high significant difference was observed (except serum creatinine and renal GSH where there was significant difference).On the other hand,a higher significant difference was observed regarding hepatic GSH.
Finally, group V(received chlorambucil for 15 days) was compared with group VIII(received Lascorbic acid concomitantly with chlorambucil for 15 days) and showed very high significant difference in all studied parameters except AST and BUN where high significant difference was observed .
Histopathological results
Examination of haematoxylin and eosin (H&E) stained sections of the liver of control (group1) showed central vein in the middle of hepatic lobules and portal tract areas were seen in the periphery. Hepatocytes were polygonal in shape with acidophilic cytoplasm and were seen with vesicular nuclei. Some hepatocytes were seen binucleated. In-between hepatic cords, blood sinusoids were noticed. The portal areas were observed containing a branch from the portal vein, a branch from the hepatic artery and a bile duct. (Figs. 1, 2) In chlorambucil treated rats for 5 days (Group III), congested dilated central veins and portal tract were observed. Vacuolated hepatocytes were also detected. Most hepatocytes were noticed with dense pyknotic nuclei . (Figs. 3,4 ) . In chlorambucil treated rats for 10 days (Group IV), hepatocytes with cytoplasmic vacuolations and congested central veins were frequently noticed. Hepatocytes with abnormal pyknotic nuclei were also detected. (Figs. 5, 6 ) While in chlorambucil treated rats for 15 days (Group V), extensive vacuolated hepatocytes with pyknotic nuclei were seen in most hepatic lobules. Dilated congested central veins, hepatic sinusoids and portal tracts were also detected. Areas of mononuclear cellular infiltration were also noticed. (Figs. 7, 8, 9) The percentage of the pathological changes observed in groups III,IV and V showed significat difference from group I. (Table 7) In rats given L-ascorbic acid concomitantly with chlorambucil for 5 days (group VI) there was mild congestion of the portal vein . (Figures 10,11 ) While those given L-ascorbic acid concomitantly with chlorambucil for 10 days (group VII) there was dilated non congested portal veins. (Figs. 12, 13) In rat group given L-ascorbic acid concomitantly with chlorambucil for 15 days (group VIII) there was congestion of some central veins and some portal tracts. Few hepatocytes were noticed with pyknotic nuclei (Figs. 14, 15) .
The percentage of pathological changes observed in groups VI,VII and VIII showed insignificant difference from group I except group VIII regarding central and portal veins congestion and dilatation where there was significant difference. (Table  7) Examination of H&E stained kidney sections of control rats (Group I ) showed renal corpuscles with glomerular tuft of capillaries. Renal corpuscles were seen surrounded by Bowman's capsule. Proximal convoluted tubules were noticed with narrow lumina. They appeared lined by pyramidal cells with acidophilic cytoplasm and basal rounded vesicular nuclei. The distal convoluted tubules were observed with wide lumina. They were lined with low cubical cells with pale acidophilic cytoplasm and rounded vesicular nuclei. (Fig 16) In rat group treated with chlorambucil for 5 days (Group III), vacuolations of some renal tubules were noticed. Some tubular cells showed pyknotic nuclei (Fig. 17) . While those treated for 10 days (Group IV ), vacoulations of renal tubular cells, pyknotic nuclei and loss of normal architecture of renal tubules could also be observed (Fig. 18 ) and chlorambucil treated rats for 15 days (Group V), congestion of peritubular capillaries, and loss of normal tubular architecture with dilatation of tubular lumen were frequently found (Figs. 19, 20) The percentage of the pathological changes observed in groups III,IV and V showed significat difference from group I. (Table 8) In rats given L-ascorbic acid concomitantly with chlorambucil for 5 days (Group VI), few tubular cells were appeared with pyknotic nuclei (Fig. 21) .
In rats given L-ascorbic acid concomitantly with chlorambucil for 10 days (Group VII), vacuolations of some renal tubular cells were observed (Fig. 22) .
While in rats given L-ascorbic acid concomitantly with chlorambucil for 15 days (Group VIII), congestion of peritubular capillaries could be detected (Fig.23) .
The percentage of pathological changes observed in groups VI,VII and VIII showed insignificant difference from group I . (Table 8 ) 
Discussion
Chlorambucil is an alkylating antineoplastic agent indicated in treatment of lymphocytic leukemia, with serious effects including hepatotoxicity, nephrotoxicity, immune-suppression etc. (Tomenendalova et al., 2008) . One of the main complications of using antineoplastic agents is the oxidative damage to normal cells during chemotherapy (Srevastava et al., 2010) This damage is due to reactive oxygen spesies which attack lipids resulting in membrane lipid peroxidation and membrane destruction (Repetto et al., 2010) Oxidative stress and lipid peroxidation are involved in various and numerous pathological states. The term "oxidative stress" is frequently used to describe the imbalances in redox couples such as reduced to oxidized glutathione (GSH/GSSG) ratio ( Hybertson et al., 2011) Reactive oxygen species (ROS) are thought to be the major ones responsible for the alteration of macromolecules which are often termed oxidative stress. ROS are generated as by-products of cellular metabolism, (Lu et al.,2010) Drugs currently used in chemotherapy acting by ROS generation. Many antitumor agents exhibit antitumor activity via ROS-dependent activation of apoptotic cell death, suggesting potential use of ROS as an antitumor agent. Thus, a unique anticancer strategy named "oxidation therapy" has been developed by inducing cytotoxic oxystress for cancer treatment. (Balaram et al.,2012) In the present study, The obtained results revealed evident hepatic damage after administration of high dose chlormabucil in the form of significant increase in ALT,AST and serum bilirubin levels as was found by Tomenendalova et al.(2008) and Summerfield et al.(2002) The damage was proved by histopathological examination as the liver of chlorambucil treated rats for 5 days, showed vacuolated hepatocytes at the periphery of classic hepatic lobule in zone 1. Extension of the lesions was noticed in rats treated for 10 days. In rats treated for 15 days, highly vacuolated hepatocytes were noticed in zone 2 and 3. It was reported that hepatic fat accumulation (steatosis) is characterized by small intracytoplasmic fat droplets that accumulate in the cell. It is due to a varied multitude of pathologies that disrupt normal lipid movement through the cell and cause accumulation (Hautekeete et al., 1990) . Therefore un-used lipids which would normally participate in lipoprotein synthesis begin to accumulate (Conde et al., 1993) .
The present results also showed marked renal dysfunction after administration of high dose chlormabucil in the form of significant elevation of blood urea nitrogen and serum createnine as was reported by Tomenendalova et al. (2008) and Blank et al.(1983) Histopathological examination showed vacoulation and loss of normal tubal architecture in kidney of chlormabucil treated rats. Extension of the lesion was noticed in rats treated for 10 days and 15 days. It was reported that alteration in integrin-which anchor tubal cells to basement membrane-led to detachment of the cells from the basement membrane and their shedding inside the lumen (Kumar et al., 2013) , this might be the cause of loss of normal tubal structure observed in this study. This also was reported by Ramadori and Cameron (2010) and Tunde et al. (2014) who reported dose dependent histological renal damage.
To prevent the damage from ROS, cells possess several antioxidant enzymes such as antioxidant defense mechanism includes nonenzymatic antioxidants such as glutathione (GSH), which functions in the cellular thiol/disulfide system (Misra et al., 2009) . It is a non enzymatic antioxidant and the primary regulatory of redox status in all cells as it is involved in scavenging hydroxyle radical and detoxification of hydrogen peroxide and lipid peroxides (Kern and Kehrer, 2005) In the present study, there was significant reduction in hepatic and renal glutathione levels after administration of high dose chlormabucil. This was reported also by Tunde et al. (2014) .
Co-administration of antioxidants with antineoplastic agents is important in reducing the toxicity of the agents (Alexieva et al., 2010) , protecting normal tissues and enhancing the killing capabilities of cancer cells (Charles et al.,2007) and (Hart, 2012) . Lascorbic acid is a good free radical scavenger due to its chemical properties (Dometrovic, 2006) , it is one of the most important lines of antioxidant defense in hepatocytes and other cells (Schafer and Buettner, 2001) In addition, Ahmed et al .(2013) and Mamede et al .(2011) observed that vitamins have been reported to play an important role in oxidative stress and cancer therapy.
In the present study, it was observed that Co treatment with L-ascorbic acid offered significant prevention of chlorambucil toxicity evidenced by significant reduction in ALT, AST and serum bilirubin levels as well as blood urea nitrogen and serum createnine levels as was found by Tunde et al. (2014) and Alexieva et al.(2010) There was also significant elevation of hepatic and renal GSH levels as was reported by Tunde et al. (2014) .
This protection was evidenced also by histopathological findings, as there was significant amelioration of histopathological changes such as mild congesttion of portal tracts, few hepatocytes with pyknotic nuclei, mild congestion of peritubular capillaries, some vaculated tubular cells with pyknotic nuclei.
Although these evidenced biochemical and histopathological improvement were more obviuos with decreasing duration of treatment, there was significant protection in each group as compared with the corresponding toxic group. Conclusion From this study it was concluded that during treatment with high dose of chlormabucil, Co treatment with Lascorbic acid is protective against hepatic and renal toxicities induced by chlorambucil.
Recommendations
According to this study, it is recommended to use L-ascorbic acid during treatment with chlorambucil, also, further researches are required to study the protective effects of using more than one antioxidant especially with long duration of chlorambucil therapy.
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